Trans-Arterial Chemoembolization with Irinotecan-Loaded Drug-Eluting Beads (DEBIRI) and Capecitabine in Refractory Liver Prevalent Colorectal Metastases: A Phase II Single-Center Study
Authors:
- Roberto IezziRoberto Iezzi
- Valentina Angela MarsicoVMValentina Angela Marsico
- Alessandra GuerraAGAlessandra Guerra
- Eleonora CerchiaroECEleonora Cerchiaro
- Alessandra CassanoACAlessandra Cassano
- Michele BassoMBMichele Basso
- Ersilia DevicientiEDErsilia Devicienti
- Elena RodolfinoERElena Rodolfino
- Carlo BaroneCBCarlo Barone
- Lorenzo BonomoLBLorenzo Bonomo
- 24 March 2015
- journal article
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 38 (6) , 1523-1531
Abstract
The purpose of this study was to evaluate feasibility, safety, tolerance, and efficacy of drug-eluting beads loaded with irinotecan (DEBIRI) in combination with capecitabine in the treatment of mCRC refractory to chemotherapy in patients affected by liver predominant metastatic disease. Twenty patients affected by CRC hepatic metastasis with liver-dominant disease, who had progression after two or more lines of chemotherapy, were enrolled. TACE with 100 mg of Irinotecan loaded into 2-ml of 70–150 µm drug-eluting beads was administrated every 4 weeks in patients with unilobar disease (2 treatments) and every 2 weeks in patients with bilobar disease (4 treatments). All patients assumed capecitabine 1000 mg/m2 twice daily on days 1–14 every 3 weeks, until disease progression. Primary endpoints were safety, tolerance and overall disease control (ODC); secondary endpoints were progression free survival (PFS) and overall survival (OS). A total of 54 treatments were performed (54/66, 82 %). No intra/peri-procedural death occurred. During the mean follow-up of 11 months, two partial responses (PR) were reported with ODC of 60 % (2 PR + 10 stable disease). PFS and OS were 4 and 7.3 months, respectively. Univariate analysis showed that patients presenting with KRAS wild-type, good ECOG performance status and unilobar disease had a better prognosis. Only performance status (ECOG) correlated with OS in multivariate analysis (p = 0.03). DEBIRI with capecitabine seem to be a safe, technically feasible and well-tolerated treatment in chemotherapy refractory liver prevalent colorectal metastases.Keywords
This publication has 21 references indexed in Scilit:
- Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancerAsia-Pacific Journal of Clinical Oncology, 2010
- Evaluation of Long-term Survival After Hepatic Resection for Metastatic Colorectal CancerAnnals of Surgery, 2008
- Actual 10-Year Survival After Resection of Colorectal Liver Metastases Defines CureJournal of Clinical Oncology, 2007
- Improving Resectability of Hepatic Colorectal Metastases: Expert Consensus StatementAnnals of Surgical Oncology, 2006
- Towards a pan-European consensus on the treatment of patients with colorectal liver metastasesEuropean Journal of Cancer, 2006
- Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR StudyJournal of Clinical Oncology, 2004
- Trends in Long-Term Survival Following Liver Resection for Hepatic Colorectal MetastasesAnnals of Surgery, 2002
- Factors influencing the natural history of colorectal liver metastasesThe Lancet, 1994